Evidence mapPaperPMID 41894036Full record

ReviewNeurochemical research2026

Considerations for Carnosine Actions in Biology.

Belisa Parmeggiani, Bruna Klippel Ferreira, Patricia Fernanda Schuck, Gustavo Costa Ferreira

Abstract readReview
In one paragraph

Review in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Belisa ParmeggianiLaboratório de Erros Inatos do Metabolismo, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0001-9688-9083
Bruna Klippel FerreiraLaboratório de Erros Inatos do Metabolismo, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0002-3329-9972
Patricia Fernanda SchuckLaboratório de Erros Inatos do Metabolismo, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.ORCID http://orcid.org/0000-0003-3148-4952
Gustavo Costa FerreiraLaboratório de Erros Inatos do Metabolismo, Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. gustavo.ferreira@bioqmed.ufrj.br.ORCID http://orcid.org/0000-0002-2892-8842

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carnosine is a histidinic dipeptide mainly identified for its pH buffering, antioxidant and metal chelating capacities. Several studies have explored the potential benefits of carnosine as a supplement for exercise, as well as an adjuvant treatment in several pathologies; however, roles and impacts of carnosine on most tissues, including the brain, are still under debate, especially in earlier stages of development. There is evidence that carnosine may impact a myriad of physiological parameters. It includes potential roles of carnosine as a modulator of cell survival, redox homeostasis, signaling and metabolism, among other functions. Many variables seem to impact the outcomes of carnosine actions (e.g., carnosine concentrations, length of exposure, target cell/tissue, biological sex, metabolic state, and developmental stage). Considering that the physiology and metabolism of histidine dipeptides change throughout life, impacts of carnosine during development should be carefully considered. This is particularly relevant in light of carnosinemia, an inherited disorder of carnosine catabolism characterized by the accumulation of carnosine and presenting neuropsychomotor dysfunction. Thus, rethinking the applications of carnosine is crucial for realization of the full potential of this promising molecule.

Indexed as

BrainCarnosineAnimalsAntioxidantsHumansAntioxidantsCarnosineBiological variablesCarnosinemiaImidazole dipeptidesStage of developmentTherapeutic potential

Identifiers

PMID41894036
PMCPMC13031222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.